Nonthymoma early-onset- and late-onset-generalized myasthenia gravis-A retrospective hospital-based study

Clinical Neurology and Neurosurgery

Volumn 109, Issue 8, 2007, Pages 686-691

  Chan, K H ^a   Cheung, R T F ^a   Mak, W ^a   Ho, S L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Acetylcholine receptor autoantibodies; Early onset myasthneia gravis; Late onset myasthenia gravis; Nonthymoma generalized myasthenia gravis; Striated muscle autoantibodies

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; IMMUNOGLOBULIN; PREDNISOLONE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY TITER; ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MALE; MYASTHENIA GRAVIS; ONSET AGE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX RATIO; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGE OF ONSET; ASIAN CONTINENTAL ANCESTRY GROUP; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; FEMALE; HONG KONG; HUMANS; MALE; MOTOR ENDPLATE; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RECEPTORS, NICOTINIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 34547844246     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2007.05.023     Document Type: Article

References (34)

1. Drachman D.B. Myasthenia gravis [review]. N Eng J Med 330 (1994) 1797-1810
2. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7 (2001) 365-368
3. Scuderi F., Marino M., Colonna L., Mannella F., Evoli A., Provenazano C., et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 82 9 (2002) 1139-1146
4. Evoli A., Ronali P.A., Padua L., Monaco M.L., Scuderi F., Batocchi A.P., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 (2003) 1-8
5. Shigemoto K., Kubo S., Maruyama N., Hato N., Yamada H., Jie C., et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 116 4 (2006) 1016-1024
6. Vincent A., and Leite M.I. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments of myasthenia gravis. Curr Opin Neurol 18 (2005) 519-525
7. Lennon V.A. Serological profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 48 Suppl 5 (1997) S23-S27
8. Williams C.L., Hay J.E., Huiatt T.W., and Lennon V.A. Paraneoplastic IgG striational autoantibodies produced by clonal thymic B-cells and in serum of patients with myasthenia gravis and thymoma react with titin. Lab Invest 66 (1992) 331-336
9. Somnier F.E., and Engel P.J. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970-1999. Neurology 59 1 (2002) 92-98
10. Ohta M., Ohta K., Itoh N., Kurobe M., Hayashi K., and Nishitani H. Anti-skeletal muscle antibodies in the sera of patients with thymoma: identification of anti-myosin, actomyosin, actin and alpha-actinin antibodies by a solid-phase radioimmunoassay and Western blotting analysis. Clin Chim Acta 187 (1990) 255-264
11. Yamamoto A.M., Gaidos P., Eymard B., Tranchant C., Warter J.M., Gomez L., et al. Anti-titin antibodies in myasthenia gravis. Arch Neurol 58 (2001) 885-890
12. Romi F., Skeie G.O., Vedeler C., Aarli J.A., Zorzato F., and Gilhus N.E. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis: a study of IgG subclasses and clinical correlations. J Neuroimmunol 111 (2000) 169-176
13. Romi F., Skeie G.O., Aarli A., and Gilhus E. The severity of myasthenia gravis correlates with the serum oncentration of titin and ryanodine receptor antibodies. Arch Neurol 57 (2000) 1596-1600
14. Skeie G.O., Mygland A., Aarli J.A., and Gilhus N.E. Titin antibodies in patients with late onset myasthenia gravis: clinical correlations. Autoimmunity 20 (1995) 99-104
15. Skeie G.O., Bartoccioni E., Evoli A., Romi F., Gilhus N.E., and Aarli J.A. Ryanodine receptor antibodies are associated with severe myasthenia gravis. Eur J Neurol 3 (1996) 136-140
16. Somnier F.E., Skeie G.O., Aarli J.A., and Trojaborg W. EMG evidence of myopathy and the occurrence of titin autoantibodies in patients with myasthenia gravis. Eur J Neurol 6 (1999) 1-9
17. Aarli J.A. Inflammatory myopathy in myasthenia gravis. Curr Opin Neurol 11 (1998) 233-234
18. Keesey J.C. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 29 (2004) 484-505
19. Aarli J.A. Late onset myasthenia gravis. Eur J Neurol 4 (1997) 203-205
20. Somnier F.E. Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65 6 (2005) 928-930
21. Vincent A., Clover L., Buckley C., Evans J.G., and Rothwell P.M. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74 8 (2003) 1105-1108
22. Griesmann G.E., and Lennon V.A. Detection of autoantibodies in myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Rose N.R., De Macario E.C., Folds J.D., Lane H.C., and Nakamura R.M. (Eds). Manual of clinical and laboratory immunology. 5th ed. (1997), ASM Press, Washington, DC 983-988
23. Slater G., Papetestas A.E., Genkins G., Kornfeld P., and Horowitz S.H. Thymectomy in patients more than 40 years of age with myasthenia gravis. Surg Gynecol Obstet 146 (1978) 54-56
24. Frist W.H., Thirumalai S., Doehring C.B., Merrill W.H., Stewart J.R., Fenichel G.M., et al. Thymectomy for the myasthenia gravis patient. Ann Thorac Surg 57 (1994) 334-338
25. de Perrot M., Licker M., and Spiliopoulos A. Factors influencing improvement and remission rates after thymectomy for myasthenia gravis. Respiration 68 6 (2001) 601-605
26. Gronseth G.S., and Barohn R.J. Practive parameters: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standard Subcommittee of the American Academy of Neurology. Neurology 55 (2000) 7-15
27. Donaldson D.H., Ansher M., Horan S., Rutherford R.B., and Ringel S.P. The relationship of age to outcome in myasthenia gravis. Neurology 40 (1990) 786-790
28. Kapinas K., Kimiskidis V.K., Kazis A.D., Kokkas B., Tsolaki M., and Georgiadis G. Myasthenia gravis: correlation of age with clinical course and anti-AchR antibody levels. Int J Immunopathol Pharmacol 12 (1999) 127-131
29. Slesak G., Melms A., Gerneth F., Sommer N., Weissert R., and Dichgans J. Late-onset myasthenia gravis: follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci 841 (1998) 777-780
30. Yu Y.L., Hawkins B.R., Ip M.S., Wong V., and Woo E. Myasthenia gravis in Hong Kong Chinese. 1. Epidemiology and adult disease. Acta Neurol Scand 86 (1992) 113-119
31. Chen W.H., Chiu H.C., and Hseih R.P. Association of HLA-Bw46DR9 combination with juvenile myasthenia gravis in Chinese. J Neurol Neurosurg Psychiatry 56 (1993) 382-385
32. Hawkins B.R., Chan-Lui W.Y., Choi E.K.K., and Ho A.Y. Strong association of HLA BW46 with juvenile onset myasthenia gravis in Hong Kong Chinese. J Neurol Neurosurg Psychiatry 47 (1984) 555-557
33. Yeh J.H., Chen W.H., Chiu H.C., and Vincent A. Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 62 (2004) 2131
34. Tackenberg B., Nitschke M., Wilcox N., Ziegler A., Nessler S., Schumm F., et al. CD45 isoform expression in autoimmune myasthenia gravis. Autoimmunity 36 2 (2003) 117-121